Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography

BJU International

Volumn 99, Issue 5, 2007, Pages 1154-1160

  Yapp, Donald T T ^a   Woo, Janet ^a   Kartono, Aileen ^a   Sy, Jonathan ^a   Oliver, Thomas ^a   Skov, Kirsten A ^a   Koch, Cameron J ^b   Adomat, Hans ^c   Dragowska, Wieslawa H ^a   Fadzli, Ladan ^c   Ruth, Thomas ^d   Adam, Michael J ^d   Green, David ^d   Gleave, Martin ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d TRIUMF   (Canada)

Author keywords

18F EF5; Androgen ablation; Hypoxia; Positron emission tomography; Prostate cancer; Shionogi tumours

Indexed keywords

ANDROGEN; ANTIANDROGEN; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; OXYGEN; RADIOPHARMACEUTICAL AGENT;

ANIMAL; ANOXIA; ARTICLE; FLOW CYTOMETRY; HUMAN; MALE; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; ANOXIA; FLOW CYTOMETRY; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MICE; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 34249951502     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06761.x     Document Type: Article

References (38)

1. Brown JM, Giaccia AJ. Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 1994; 65: 95-102 (Pubitemid 24063535)
2. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48
3. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005; 27: 622-38 (Pubitemid 40961072)
4. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15 (Pubitemid 26330463)
5. Brizel DM, Scully SP, Harrelson JM et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3 (Pubitemid 26065381)
6. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-9 (Pubitemid 27318643)
7. Movsas B, Chapman JD, Hanlon AL et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60: 634-9 (Pubitemid 35246449)
8. Movsas B, Chapman JD, Hanlon AL et al. Hypoxia in human prostate carcinoma: an Eppendorf pO2 study. Am J Clin Oncol 2001; 24: 458-61 (Pubitemid 32959102)
9. Rasey JS, Koh WJ, Evans ML et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-28
10. Movsas B, Chapman JD, Greenberg RE et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 2000; 89: 2018-24
11. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300 (Pubitemid 27318990)
12. Pilepich MV, Krall JM, al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-23
13. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44: 809-19 (Pubitemid 29284129)
14. Robnett TJ, Whittington R, Malkowicz SB et al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 1146-51 (Pubitemid 34787849)
15. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997; 3: 31-6
16. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38: 1067-70 (Pubitemid 27353687)
17. Skov K, Adomat H, Bowden M et al. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res 2004; 162: 547-53 (Pubitemid 39600543)
18. McNab JA, Yung AC, Kozlowski P. Tissue oxygen tension measurements in the Shionogi model of prostate cancer using MRS and MRI. MAGMA 2004; 17: 288-95
19. Rothermund CA, Gopalakrishnan VK, Eudy JD, Vishwanatha JK. Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC Urol 2005; 5: 5
20. Meng AX, Jalali F, Cuddihy A et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005; 76: 168-76 (Pubitemid 41725444)
21. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76 (Pubitemid 32219813)
22. Dragowska WH, Warburton C, Yapp DT et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res 2004; 2: 606-19 (Pubitemid 39557664)
23. Ziemer LS, Evans SM, Kachur AV et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003; 30: 259-66 (Pubitemid 36686845)
24. Rennie PS, Bruchovsky N, Buttyan R, Benson M, Cheng H. Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res 1988; 48: 6309-12
25. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995; 72: 869-74
26. Tai YC, Ruangma A, Rowland D et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005; 46: 455-63 (Pubitemid 43093155)
27. Bruchovsky N, Rennie PS. Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogenous patterns of androgen binding. Cell 1978; 13: 273-80 (Pubitemid 8309863)
28. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000; 60: 3058-64 (Pubitemid 30395835)
29. Nickerson T, Miyake H, Gleave ME, Pollak M. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 1999; 59: 3392-5 (Pubitemid 29334498)
30. So AI, Bowden M, Gleave M. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours. BJU Int 2004; 93: 845-50 (Pubitemid 38497041)
31. Kozlowski P, Wong J, Goldenberg SL. Serial tumour blood-flow measurements in androgen-dependent and -independent Shionogi tumour models. BJU Int 2005; 95: 644-9 (Pubitemid 40311490)
32. Olive PL, Aquino-Parsons C. Measurement of tumor hypoxia using single-cell methods. Semin Radiat Oncol 2004; 14: 241-8 (Pubitemid 38903228)
33. Olive P, Trotter T, Banath JP, Jackson SM, Le Riche J. Heterogeneity in human tumour hypoxic fraction using the comet assay. Br J Cancer Suppl 1996; 27: S191-5 (Pubitemid 26237959)
34. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177-83 (Pubitemid 29044189)
35. Evans SM, Fraker D, Hahn SM et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2006; 64: 922-7 (Pubitemid 43183594)
36. 2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 2006; 80: 123-31
37. Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 2006; 50: 28-43
38. 19F-NMR. XII Meeting of ISMRM, Kyoto May 2004: 2037